Bristol Myers Squibb Company $BMY Shares Sold by HighTower Advisors LLC

Key Points

• HighTower Advisors reduced its Bristol Myers Squibb stake by 2.3% in the second quarter, selling 26,606 shares and retaining 1.13 million shares valued at approximately $64.9 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported quarterly earnings of $2.04 per share, exceeding the $1.60 consensus estimate, while revenue rose 5.7% year over year to $12.97 billion. The company maintains fiscal 2026 EPS guidance of $6.75–$7.00.
• The company pays a quarterly dividend of $0.63, equivalent to an annualized $2.52 dividend and a 3.8% yield. Analysts have a “Moderate Buy” consensus rating with an average price target of $66.06.

HighTower Advisors LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 2.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,126,721 shares of the biopharmaceutical company's stock after selling 26,606 shares during the quarter. HighTower Advisors LLC owned about 0.06% of Bristol Myers Squibb worth $64,922,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Davis Asset Management L.P. bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $27,000. Swiss RE Ltd. bought a new position in Bristol Myers Squibb in the 4th quarter worth about $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $32,000. Finally, Bayban acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 0.0%

BMY opened at $66.85 on Tuesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market capitalization of $136.56 billion, a PE ratio of 14.72, a P/E/G ratio of 0.32 and a beta of 0.23. The stock's fifty day moving average is $63.09 and its 200-day moving average is $59.96. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company's quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb's payout ratio is currently 55.51%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on BMY shares. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday, August 5th. Sanford C. Bernstein upgraded Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research report on Wednesday, August 5th. Bank of America decreased their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating for the company in a research note on Friday, July 10th. Royal Bank Of Canada lifted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a research note on Friday, July 31st. Finally, Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an "overweight" rating for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Insider Activity

In related news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.